Delivery Order SPE2DB22D2218-SPE2DB25FR3JD
- Not listed
- The Defense Logistics Agency awarded a $41,480.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Rexulti 1 mg tablets (30-count units). This firm fixed-price, competitively awarded contract with an ultimate completion date of July 29, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Rexulti 1 mg tablets in a 30-count package, with a contract ceiling value of $4,260.21. This non-set-aside, competitively awarded delivery order represents a firm fixed price transaction and is scheduled for completion by August 15, 2025. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $4,508.41 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count package) on August 18, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and represents a small-value transaction within the company's extensive pharmaceutical distribution portfolio for federal medical procurement. The product will be...
- The Defense Logistics Agency awarded a delivery order valued at $30,339.39 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed price arrangement. The award, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's larger contract vehicle. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Rexulti 2 mg tablets (quantity: 30 units) with a ceiling value of $2,927.61. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $15,422.40 to AmerisourceBergen Drug Corp for 30 tablets of Rexulti 0.5 mg on August 18, 2025, with completion targeted for August 19, 2025. This competitively awarded, firm fixed-price contract requires delivery to AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a $3,903.48 delivery order to AmerisourceBergen Drug Corp for 30 tablets of Rexulti 2 mg on July 28, 2025, with completion scheduled for July 29, 2025. This firm fixed-price delivery order is issued without set-aside designation, indicating open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location. The award represents a child order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Rexulti 2 mg tablets in a quantity of 30 units, with a ceiling value of $2,927.61. This is a firm fixed price delivery order with an ultimate completion date of August 11, 2025, and represents a non-competitive set-aside award. The order will be performed at the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This...
- The Defense Logistics Agency awarded a delivery order valued at $23,256.95 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed-price contract. This non-set-aside award was issued on August 22, 2025, with an ultimate completion date of August 25, 2025, and represents a pharmaceutical delivery to support federal medical procurement needs. The contract is executed from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $8,861.23 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on September 4, 2025, with an ultimate completion date of September 5, 2025, and does not utilize a set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this delivery order. This delivery order...
- SPE2DB22D2218Indefinite Delivery Contract
- SPE2DB22D2218-SPE2DB25FR3JDDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,458.34 to AmerisourceBergen Drug Corp for 30 tablets of Rexulti 2 mg on September 11, 2025, with completion scheduled for September 12, 2025. This firm fixed-price, non-set-aside contract represents a pharmaceutical supply delivery executed through AmerisourceBergen's existing indefinite delivery contract vehicle with DLA Troop Support Medical. The contractor, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal military and veteran healthcare systems with a comprehensive portfolio of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains. This delivery order is issued under AmerisourceBergen's DLA Troop Support Medical prime IDC (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which enables the company to supply pharmaceutical products and medical commodities globally to support military healthcare programs. Rexulti, an atypical antipsychotic medication, reflects the contractor's role in fulfilling specialized neurological and psychiatric medication needs for the Defense Health Agency and other federal healthcare beneficiaries. As a child order under this comprehensive pharmaceutical support vehicle, the delivery order demonstrates the flexibility and efficiency of the DLA's indefinite delivery contract approach in meeting routine medical supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.5k | 9/11/25 |